Bio Pharma Dive
OCTOBER 8, 2020
Recent deals for MyoKardia and The Medicines Co. may be hard to follow, since venture investors and big pharma acquirers have largely ignored cardiovascular drugs.
World of DTC Marketing
OCTOBER 6, 2020
WHAT’S THIS ABOUT THEN : Researchers are rushing to launch clinical trials of experimental vaccines against the coronavirus, and treatments for COVID-19. But as hospitals brace for an onslaught of critically ill patients and laboratories worldwide are disrupted, researchers have had to shelve clinical trials of therapies for other illnesses. Eli Lilly recently announced that it would halt enrolment in ongoing studies and delay the launch of new trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
OCTOBER 6, 2020
One of the biggest medical advancements of recent times is the invention of the cell isolation method. Also known as cell sorting or cell separation, the cell isolation method has rapidly become an integral component of modern biological and medical research. In this method, a one-cell population or multiple cell types are isolated from a. The post How is Cell Isolation Revolutionizing Medical Industry?
pharmaphorum
OCTOBER 7, 2020
Better management of customer data could help pharmaceutical companies’ digital transformation, according to Veeva’s Rebecca Silver. pharmaphorum’s Richard Staines spoke to her about how the use of customer reference data can transform pharma companies, increase competitiveness, and benefit the bottom line during these challenging times. Precision medicine is emerging as a key approach for disease treatment and prevention, which makes it even more critical to get the right medicine to the
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
OCTOBER 8, 2020
The biotech, a frontrunner in the coronavirus vaccine race, said it won't tie up resources defending the intellectual property covering its experimental shot as long as the pandemic continues.
World of DTC Marketing
OCTOBER 9, 2020
HERE’S THE PITCH: Guidelines surrounding effective frequency are different by every advertised product. For pharma products, effective frequency is, for example, the frequency at which someone is going to go online to learn more about your product. TV alone is not going to sell your product. You need to invest in digital marketing too. DTC marketers should be joined at the hip with their market research people.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
NY Times
OCTOBER 4, 2020
Many of the measures cited by his doctors are reserved for patients severely affected by the coronavirus.
Bio Pharma Dive
OCTOBER 6, 2020
The review criteria outlined in the document, which the White House had held up for weeks, make the early approval of a coronavirus shot before the Nov. 3 election less likely.
Outsourcing Pharma
OCTOBER 8, 2020
A veteran with more than 20 years of experience talks about the vitality of recruiting an inclusive patient population, and the perils of falling short.
Pharma Times
OCTOBER 8, 2020
New agreement allows countries in the EU, EEA and the UK to purchase drug
Camargo
OCTOBER 8, 2020
Throughout the life-cycle of a drug development program, sponsors are confronted with a range of key questions. They must decide on the correct…. Regulatory pathway, FDA center, Key Opinion Leaders (KOLs), Target Product Profile (TPP) inclusions, Data to rely on, Studies to conduct, Indication and patient population, Commercial strategy, and much more.
Bio Pharma Dive
OCTOBER 7, 2020
The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination.
Pharma Mirror
OCTOBER 7, 2020
Romaco has appointed a Sustainability Officer and defined goals for the company’s climate-friendly development. Not only is the manufacturer seeking to enable more sustainable production by its customers; Romaco is also keen to improve its own carbon footprint. The Romaco Group has a new central corporate objective: sustainability. To enable climate protection measures to be.
Pharma Times
OCTOBER 9, 2020
Fadraciclib has passed safety trials and shown early efficacy
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
OCTOBER 6, 2020
An Excel spreadsheet was behind IT glitch that caused thousands of positive COVID-19 tests to be omitted from the UK’s official records, according to press reports. The issue that left almost 16,000 positive results going unreported has been blamed on the way Public Health England tracks results from mainly private labs that have been hired to add extra testing capacity.
Bio Pharma Dive
OCTOBER 7, 2020
Personalized, insight-driven omnichannel marketing has never been more beneficial or important.
Pharma Mirror
OCTOBER 6, 2020
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the market release of SeptiCyte® RAPID on Idylla™ as a CE-marked IVD test. SeptiCyte® RAPID is a host-response test that distinguishes sepsis from non-infectious systemic inflammation in patients suspected of sepsis and provides actionable results in about one.
Pharma Times
OCTOBER 5, 2020
Combination treatment did not achieve statistical significance in all-comer population
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
NY Times
OCTOBER 8, 2020
The “cell lines” used to develop monoclonal antibodies, as well as remdesivir and vaccines, began with fetal tissue decades ago.
Bio Pharma Dive
OCTOBER 5, 2020
The availability of three vastly different, cutting-edge medicines for the rare disease has put patients, families and doctors in an unfamiliar position.
Pharma Mirror
OCTOBER 5, 2020
Informa Markets announces its complete listing of pharma event dates for 2021 at the opening of the first CPhI Festival of Pharma (05 – 16 October 2020) – the largest ever virtual pharma event. The pharma schedule includes one further event in 2020: CPhI China, 16-18 December (hybrid event, combining “live” in-person with “virtual”). In. The post Full CPhI & Pharmapack Europe schedule returns in 2021 with live & hybrid events appeared first on Pharma Mirror Magazine.
Pharma Times
OCTOBER 5, 2020
Gene therapy demonstrated improvement in retinal sensitivity
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
OCTOBER 5, 2020
Digital health firm Your.MD has secured $30 million in a Series A round investment led by the consumer health giant Reckitt Benckiser (RB). Your.MD is the company behind the medical-grade, augmented intelligence self-care app Healthily, and will use the funding to accelerate the platform through a series of clinically-validated “health hubs”. Following a seed funding round led by RB and existing shareholders, the now completed Series A funding round will allow the app to reach other markets incl
Bio Pharma Dive
OCTOBER 6, 2020
Blocked by the White House from issuing new vaccine guidelines, the FDA made its criteria for an emergency authorization clear anyway, publishing requirements it had previously communicated to drugmakers.
Drug Patent Watch
OCTOBER 6, 2020
Here is a copy of the talk I gave at the recent Marcusevans 13th Portfolio Management and Pipeline Optimization for Generics. I cover: How to find and evaluate generic entry…. The post Finding and Evaluating Generic Drug Market Entry Opportunities appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
OCTOBER 6, 2020
Two-drug regimen continues to offer non-inferior efficacy compared to a three-drug regimen
BioSpace
OCTOBER 6, 2020
There is little doubt that CRISPR gene editing is and will continue to revolutionize biology and medicine. The Nobel Committee confirmed their belief in that by awarding the Nobel Prize in Chemistry to Emmanuelle Charpentier and Jennifer A. Doudna for their discovery and development of CRISPR.
Bio Pharma Dive
OCTOBER 8, 2020
The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use.
pharmaphorum
OCTOBER 7, 2020
Axovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from a small cohort of patients from a phase 2 trial. However shares in Axovant were down sharply after the announcement because of market sentiment that the New York biotech had been selective with the data it had shared in its update.
Pharma Times
OCTOBER 7, 2020
Potential disease modifying osteoarthritis candidate is phase II ready
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
361 
Let's personalize your content